
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
September days are crisper, and President and Congress have returned from summer vacation. It's time to confront the legislative agenda, pass the 13 appropriation bills that keep the federal government functioning, and bring pending legislation to a conclusion.






